Our study was, therefore, designed to measure changes within the members of the ECS and members now regarded as part of the endocannabinoidome (e.g. GPR55, GPR119, PPARs, PEA, OEA, LPI etc.)11 in human IBD and CRC to evaluate potential targets for pharmacological therapy. Here, GPR55 is linked to inflammatory bowel disease.